166 related articles for article (PubMed ID: 30348533)
21. Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994-2004.
Alsina M; Marcos-Gragera R; Capdevila J; Buxó M; Ortiz RM; Barretina P; Vilardell L; Brunet J; Beltran M; Izquierdo Á
Cancer Epidemiol; 2011 Dec; 35(6):e49-54. PubMed ID: 21840785
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population-based study.
Tian FX; Cai YQ; Zhuang LP; Chen MF; Xiu ZB; Zhang Y; Liu H; Liu ZH; Liu GP; Zeng C; Lin FL; Liu J; Huang ST; Zhang LZ; Lin HY
Cancer Med; 2018 Nov; 7(11):5359-5369. PubMed ID: 30311450
[TBL] [Abstract][Full Text] [Related]
23. Neuroendocrine tumor epidemiology: contrasting Norway and North America.
Hauso O; Gustafsson BI; Kidd M; Waldum HL; Drozdov I; Chan AK; Modlin IM
Cancer; 2008 Nov; 113(10):2655-64. PubMed ID: 18853416
[TBL] [Abstract][Full Text] [Related]
24. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
25. Life expectancy in pancreatic neuroendocrine cancer.
Brooks JC; Shavelle RM; Vavra-Musser KN
Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):88-97. PubMed ID: 30220478
[TBL] [Abstract][Full Text] [Related]
26. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors.
Shen C; Gu D; Zhou S; Xu Y; Sarshekeh AM; Halperin D; Shih YT; Yao JC; Dasari A
Pancreas; 2019; 48(10):1373-1379. PubMed ID: 31688604
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.
Zhai H; Li D; Feng Q; Qian X; Li L; Yao J
Int J Surg; 2019 Jun; 66():103-109. PubMed ID: 30872175
[TBL] [Abstract][Full Text] [Related]
28. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
29. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
30. Second primary cancers and survival among neuroendocrine tumor patients.
Bateni SB; Coburn NG; Law C; Singh S; Myrehaug S; Assal A; Hallet J
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184947
[TBL] [Abstract][Full Text] [Related]
31. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.
Hallet J; Law CH; Cukier M; Saskin R; Liu N; Singh S
Cancer; 2015 Feb; 121(4):589-97. PubMed ID: 25312765
[TBL] [Abstract][Full Text] [Related]
32. 20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes:
Milano AF
J Insur Med; 2019; 48(1):5-23. PubMed ID: 31609640
[No Abstract] [Full Text] [Related]
33. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors.
Kauffmann RM; Wang L; Phillips S; Idrees K; Merchant NB; Parikh AA
Ann Surg Oncol; 2014 Oct; 21(11):3422-8. PubMed ID: 25059786
[TBL] [Abstract][Full Text] [Related]
34. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan.
Chang JS; Chen LT; Shan YS; Chu PY; Tsai CR; Tsai HJ
Sci Rep; 2021 Apr; 11(1):7881. PubMed ID: 33846396
[TBL] [Abstract][Full Text] [Related]
35. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
36. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms.
Leoncini E; Boffetta P; Shafir M; Aleksovska K; Boccia S; Rindi G
Endocrine; 2017 Nov; 58(2):368-379. PubMed ID: 28303513
[TBL] [Abstract][Full Text] [Related]
37. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
Shen C; Shih YC; Xu Y; Yao JC
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
[TBL] [Abstract][Full Text] [Related]
38. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database.
Broder MS; Cai B; Chang E; Neary MP
BMC Pulm Med; 2018 Aug; 18(1):135. PubMed ID: 30103725
[TBL] [Abstract][Full Text] [Related]
39. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
40. Trends in diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in India: A report of multicenter data from a web-based registry.
Palepu J; Shrikhande SV; Bhaduri D; Shah RC; Sirohi B; Chhabra V; Dhar P; Sastry R; Sikora S
Indian J Gastroenterol; 2017 Nov; 36(6):445-451. PubMed ID: 29457213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]